🇬🇧 AstraZeneca PLC (LSE: AZN) — August 2025 Snapshot
AstraZeneca is a leading British-Swedish biopharmaceutical company headquartered in Cambridge, UK. It’s renowned for its work in oncology, cardiovascular, respiratory, and rare diseases, and remains a pillar of the FTSE 100 index.
📊 Share Price & Market Performance
- Current Share Price: 11,738.00p
- 52-Week Range: 9,573.51p – 13,388.00p
- Market Capitalisation: £179.76 billion
- 1-Year Return: –8%
- Year-to-Date: +10%
After a challenging 2024, AstraZeneca has shown resilience in 2025, buoyed by strong quarterly results and renewed investor confidence.
📉 Valuation Metrics
| Metric | Value | Commentary |
|---|---|---|
| P/E Ratio | 25.87 | Reflects a fair valuation for a mature pharmaceutical firm |
| PEG Ratio | ~1.30 | Indicates growth is reasonably priced |
🧾 Q2 2025 Financial Highlights
- Revenue: $14.46 billion (exceeded expectations)
- Net Profit: $2.45 billion
- Adjusted EPS: $1.09 (in line with forecasts)
- Growth Drivers: Oncology portfolio, rare disease treatments, and strong performance in China
💷 Dividend Profile
- Dividend Yield: ~2.2%
- Payout Ratio: ~55%
- Next Earnings Date: November 2025 (Q3)
AstraZeneca continues to offer a reliable dividend, underpinned by healthy cash flow and a robust development pipeline.
🔭 Strategic Outlook
- Expanding footprint in emerging markets, particularly Asia
- Investing heavily in gene therapy and immunology
- Targeting $45 billion in annual revenue by 2030
